227 related articles for article (PubMed ID: 19820906)
41. [Alternatives to surgical treatment of adenocarcinomas of the esophagus and the cardia].
Seitz JF
Gastroenterol Clin Biol; 1994; 18(1 Pt 2):D67-70. PubMed ID: 8013789
[No Abstract] [Full Text] [Related]
42. [Value of postoperative radiochemotherapy with 5-fluorouracil plus leucovorin in stage IB-IV M0 stomach carcinoma].
Hehr T; Adamek HE
Strahlenther Onkol; 2002 Mar; 178(3):164-6. PubMed ID: 11962195
[No Abstract] [Full Text] [Related]
43. [Laser and afterloading therapy: esophageal cancer].
Dittler HJ
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():185-91. PubMed ID: 1724195
[TBL] [Abstract][Full Text] [Related]
44. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
45. Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
Kolh P; Honore P; Degauque C; Gielen J; Gerard P; Jacquet N
Eur J Cardiothorac Surg; 2000 Sep; 18(3):293-300. PubMed ID: 10973538
[TBL] [Abstract][Full Text] [Related]
46. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Lustberg MB; Bekaii-Saab T; Young D; Otterson G; Burak W; Abbas A; McCracken-Bussa B; Lustberg ME; Villalona-Calero MA
J Thorac Oncol; 2010 May; 5(5):713-8. PubMed ID: 20354452
[TBL] [Abstract][Full Text] [Related]
47. [Value of radiotherapy and chemotherapy in treatment of operable cancers of the esophagus].
Msika S; Hay JM
J Chir (Paris); 2002 Feb; 139(1):17-24. PubMed ID: 12071024
[TBL] [Abstract][Full Text] [Related]
48. [Concomitant chemoradiotherapy of cancer of the esophagus].
Calais G
Cancer Radiother; 1998 Dec; 2(6):689-95. PubMed ID: 9922774
[TBL] [Abstract][Full Text] [Related]
49. [Combined preoperative radiochemotherapy in squamous cell carcinoma. The view of the medical oncologist].
Stahl M
Chirurg; 2009 Nov; 80(11):1006-10. PubMed ID: 19730797
[TBL] [Abstract][Full Text] [Related]
50. [Esophageal carcinoma: guidelines in surgical therapy].
Kremer B; Marxsen J; Grimm H; Stoffregen C; Schmid A; Henne-Bruns D
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():284-9. PubMed ID: 9931626
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant therapy for esophageal cancer: standard of care or elusive myth?
Boyle MJ; Franceschi D; Robinson DS; Livingstone AS
Am Surg; 2001 Oct; 67(10):956-65. PubMed ID: 11603553
[TBL] [Abstract][Full Text] [Related]
52. Long-term results of a phase-II-pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract.
Berdel WE; Heldmann T; Thiel E
Oncol Rep; 2001; 8(2):341-2. PubMed ID: 11182052
[TBL] [Abstract][Full Text] [Related]
53. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.
Bollschweiler E; Metzger R; Drebber U; Baldus S; Vallböhmer D; Kocher M; Hölscher AH
Ann Oncol; 2009 Feb; 20(2):231-8. PubMed ID: 18836090
[TBL] [Abstract][Full Text] [Related]
54. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
[TBL] [Abstract][Full Text] [Related]
55. Individualized surgical strategies for cancer of the esophagogastric junction.
Stein HJ; Feith M; Siewert JR
Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
[TBL] [Abstract][Full Text] [Related]
56. Biology of esophageal cancer and the role of combined modality therapy.
Thomas CR
Surg Clin North Am; 1997 Oct; 77(5):1139-67. PubMed ID: 9347835
[TBL] [Abstract][Full Text] [Related]
57. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
Zhou YJ; Lu XF; Meng JL; Wang XY; Zhang QW; Chen JN; Wang QW; Yan FR; Li XB
BMC Cancer; 2021 Jul; 21(1):771. PubMed ID: 34217249
[TBL] [Abstract][Full Text] [Related]
58. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract.
Matuschek C; Bölke E; Peiper M; Knoefel WT; Budach W; Erhardt A; Scherer A; Gerber PA; Buhren BA; Gattermann N; Baldus SE; Rusnak E; Shukla V; Orth K
Eur J Med Res; 2011 Jun; 16(6):265-74. PubMed ID: 21810561
[TBL] [Abstract][Full Text] [Related]
59. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
60. Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience.
Díaz R; Reynes G; Tormo A; de Juan M; Gironés R; Segura A; Aparicio J; Richart P; de la Cueva H; García J
Clin Transl Oncol; 2009 Dec; 11(12):835-41. PubMed ID: 20045790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
